Company Overview


At Delta TpX, we are using optimized human enzymes to target small molecule immune messengers and regulators of the tumor microenvironment. These pathways of immune evasion have been largely unexplored but can be drivers of cancer growth and proliferation.


Our vision is to apply innovative cancer research to develop novel therapies that target small molecule immune messenger pathways that play a role in escape from antitumor immunity.


Today’s cancer immunotherapies effectively harness the immune system to attack tumors, control cancer growth, and in many cases, eliminate cancer. Such therapies hold the potential to address a broad spectrum of cancers; however, only a subset of patients respond to currently available treatments. There is a clear need to develop therapeutics that reverse additional mechanisms of tumor immunosuppression or that can enhance the activity of immunotherapies to counteract resistance.

Resistance derives from tumor intrinsic factors that enable the cancer to evade immune surveillance, but also from the complex interplay between cancer and its microenvironment. In particular, immunosuppressive metabolites within the tumor microenvironment (TME) are emerging as major drivers in evading immune surveillance. Enzyme therapeutics provide a highly specific means of blocking immune messengers that cannot otherwise be effectively achieved with antibody or small molecule antagonists. Our pipeline of engineered human therapeutic enzymes has the potential to change cancer care.

Lead Molecule

DTX-5500 – An immunooncology-based therapeutic addressing the largest genetically targeted therapeutic opportunity in cancer, the loss of methylthioadenosine phosphorylase gene (MTAP). This engineered human enzyme addresses a novel mechanism of tumor-induced immune suppression by 5’ methylthioadenosine (MTA), which is the substrate of the MTAP enzyme. When the MTAP tumor suppressor gene is lost by deletion of chromosome 9p21.3, the most common chromosome deletion in cancer, MTA is secreted to the tumor microenvironment where it inhibits anti-tumor immunity.


ADENOSINE TARGETING – The second molecule under development in our pipeline is an engineered human enzyme that degrades adenosine. There are multiple pathways by which adenosine can be produced in the tumor microenvironment. Targeting the immunosuppressive activity of adenosine by enzyme-mediated degradation addresses both diverse sources of adenosine production and a variety of receptor subtypes.

PLATFORM – Delta’s novel platform technology is expected to quickly generate additional clinical candidates that address other targets in the immune environment and enhance the activity of the immune system.